Search Results - "Post, J P van der"

  • Showing 1 - 16 results of 16
Refine Results
  1. 1

    Biomarkers for the effects of benzodiazepines in healthy volunteers by De Visser, S. J., Van Der Post, J. P., De Waal, P. P., Cornet, F., Cohen, A. F., Van Gerven, J. M. A.

    Published in British journal of clinical pharmacology (01-01-2003)
    “…Studies of novel centrally acting drugs in healthy volunteers are traditionally concerned with kinetics and tolerability, but useful information may also be…”
    Get full text
    Journal Article
  2. 2

    The central nervous system effects, pharmacokinetics and safety of the NAALADase‐inhibitor GPI 5693 by Van Der Post, J. P., De Visser, S. J., De Kam, M. L., Woelfler, M., Hilt, D. C., Vornov, J., Burak, E. S., Bortey, E., Slusher, B. S., Limsakun, T., Cohen, A. F., Van Gerven, J. M. A.

    Published in British journal of clinical pharmacology (01-08-2005)
    “…Aim The aim was to assess the central nervous system (CNS) effects, pharmacokinetics and safety of GPI 5693, an inhibitor of a novel CNS‐drug target, NAALADase…”
    Get full text
    Journal Article
  3. 3

    Pharmacokinetic/pharmacodynamic Assessment of Tolerance to Central Nervous System Effects of a 3 mg Sustained Release Tablet of Rilmenidine in Hypertensive Patients by van der Post, J. P., de Visser, S. J., Schoemaker, R. C., Cohen, A. F., van Gerven, J. M. A.

    Published in Journal of psychopharmacology (Oxford) (01-06-2004)
    “…Previous single-dose studies have shown clear blood pressure-lowering effects of a potential sustained release (SR) profile of rilmenidine, with…”
    Get full text
    Journal Article
  4. 4

    Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa by Smarius, LJCA, Jacobs, GE, Hoeberechts-Lefrandt, DHM, de Kam, ML, van der Post, JP, de Rijk, R, van Pelt, J, Schoemaker, RC, Zitman, FG, van Gerven, JMA, Gijsman, HJ

    Published in Journal of psychopharmacology (Oxford) (01-06-2008)
    “…5-hydroxytryptophan (5-HTP) is a direct 5-hydroxytryptamine (5-HT) precursor used to assess central serotonergic function. Its use has been limited by a narrow…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7
  8. 8

    Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA alpha2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers by de Haas, S L, de Visser, S J, J P van der Post, de Smet, M

    Published in Journal of psychopharmacology (Oxford) (01-06-2007)
    “…TPA023, a GABAA alpha2,3 subtype-selective partial agonist, is expected to have comparable anxiolytic efficacy as benzodiazepines with reduced sedating…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13

    Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA [alpha]2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers by de Haas, SL, de Visser, SJ, van der Post, JP, Schoemaker, RC, van Dyck, K, Murphy, MG, de Smet, M, Vessey, LK, Ramakrishnan, R, Xue, L, Cohen, AF, van Gerven, JMA

    Published in Journal of psychopharmacology (Oxford) (01-01-2008)
    “…The use of non-selective γ-aminobutyric acid (GABA) enhancers, such as benzodiazepines in the treatment of anxiety disorders is still widespread but hampered…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16

    Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients by Visser, Saco J., Post, Jeroen‐Paul, Nanhekhan, Loyd, Schoemaker, Rik C., Cohen, Adam F., Gerven, Joop M. A.

    Published in Clinical pharmacology and therapeutics (01-10-2002)
    “…Objectives This study was designed to assess the concentration‐effect relationships for the antihypertensive effects of rilmenidine in patients to aid in the…”
    Get full text
    Journal Article